Assessing laboratory capacity for diagnosis of fungal infections in France: A multicentre survey within the SINFONI network
Medical Mycology · 01.05.2026 · 64 (5)
DOI: 10.1093/mmy/myag050 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Medical Mycology, online erschienen am 14.05.2026. Verfasst von Florent Morio und 57 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, CHU Nantes, IICiMed, UR 1155, F-44200 Nantes, France. Hauptthemen laut MEDLINE: Invasive Fungal Infections, Clinical Laboratory Techniques, Mycoses. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Santé Publique France.
Abstract (Originalsprache)
Invasive fungal diseases are life-threatening complications, particularly in immunocompromised patients, and require rapid and accurate diagnosis to improve clinical outcomes. Although major advances in fungal diagnostics that includes antigen detection, molecular assays, and Matrix-Assisted Laser Desorption/Ionization – Time Of Flight (MALDI-TOF) mass spectrometry, have transformed diagnostic strategies, access to these tools remains heterogeneous. In France, national data on diagnostic capacities for invasive fungal diseases have been lacking. Using the framework of the national prospective surveillance program for invasive fungal diseases (SINFONI network), we conducted a survey to assess laboratory diagnostic practices in France. A secured 116-item questionnaire was distributed to 58 participating laboratories, of which 48 responded (83%). Automated blood culture systems and MALDI-TOF mass spectrometry for yeast identification were universally available, with 40 (83%) of the 48 participating laboratories also using MALDI-TOF for mould identification. Antifungal susceptibility testing was performed on-site in 47 (98%) centres for yeasts and in 37 (77%) for moulds. Antigen-based biomarkers were widely available on-site, particularly cryptococcal antigen (n = 43, 90%) and Aspergillus galactomannan (n = 39, 81%), whereas β-D-glucan testing was available in only 26 (54%) of the centres. PCR-based diagnostics were implemented on-site in 43 (88%) centres, most commonly for Pneumocystis jirovecii, Aspergillus spp., and Mucorales. Systematic screening for Candidozyma auris colonization in at-risk patients was performed in 30 (63%) centres, predominantly using culture-based methods (n = 24). Overall, this survey provides the first national overview of diagnostic capacities for invasive fungal diseases in France, highlighting a strong laboratory mycology infrastructure while identifying remaining gaps in access to specific biomarkers, molecular assays, and mould antifungal susceptibility testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nantes Université, CHU Nantes, IICiMed, UR 1155, F-44200 Nantes, France.
- Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Translational Mycology research group, Mycology Department, F-75015 Paris, France.
- Laboratoire de parasitologie-mycologie, AP-HP, Hôpital Saint-Louis, F-75010 Paris, France.
- Laboratoire de Parasitologie-Mycologie Hôpital Necker APHP - Université Paris Cité, F-75015 Paris, France.
- Université Marie et Louis Pasteur, CHU Besançon, CNRS, Chrono-environnement (UMR 6249), F-25000 Besançon, France.
- Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier d'Ajaccio, F-2A, Ajaccio, France.
ORCID-Profile: Florent Morio, Dea Garcia-Hermoso, Eric Dannaoui, Laurence Millon, Olivier Lortholary, Taieb Chouaki, Anne-Pauline Bellanger, Maxime Lefranc, Maxime Moniot, Laure Kamus, Nicole Desbois-Nogard, Christine Bonnal, Maud Gits-Muselli, Juliette Guitard, Caroline Mahinc, Guillaume Desoubeaux, Elisabeth Chachaty, Marie Desnos-Ollivier
Förderung
- Santé Publique France
Zitieren
APA
Morio, F., Alanio, A., Boukris-Sitbon, K., Garcia-Hermoso, D., Dannaoui, E., Millon, L., Lortholary, O., Obadia, T., Boyer-Chammard, T., Chouaki, T., Pihet, M., Dorin, J., Bellanger, A. P., Brun, S., Lefranc, M., Chateau, I., Bonhomme, J., Moniot, M., Botterel, F., …, & Desnos-Ollivier, M. (2026). Assessing laboratory capacity for diagnosis of fungal infections in France: A multicentre survey within the SINFONI network. Medical Mycology, 64(5). https://doi.org/10.1093/mmy/myag050
Vancouver
Morio F, Alanio A, Boukris-Sitbon K, Garcia-Hermoso D, Dannaoui E, Millon L, et al. Assessing laboratory capacity for diagnosis of fungal infections in France: A multicentre survey within the SINFONI network. Medical Mycology. 2026;64(5). doi:10.1093/mmy/myag050
BibTeX
@article{Morio2026,
author = {Morio, Florent and Alanio, Alexandre and Boukris-Sitbon, Karine and Garcia-Hermoso, Dea and Dannaoui, Eric and Millon, Laurence and Lortholary, Olivier and Obadia, Thomas and Boyer-Chammard, Timothée and Chouaki, Taieb and Pihet, Marc and Dorin, Joséphine and Bellanger, Anne-Pauline and Brun, Sophie and Lefranc, Maxime and Chateau, Iona and Bonhomme, Julie and Moniot, Maxime and Botterel, Françoise and Basmaciyan, Louise and Dalle, Fréderic and Garnaud, Cécile and Jeddi, Fakhri and Haboub, Marwan and Kamus, Laure and Chassagne, Claire and Loridant, Séverine and Cornu, Marjorie and Durieux, Marie-Fleur and Desbois-Nogard, Nicole and Pasquier, Grégoire and Cottrel, Claire and Moquet, Olivier and Hasseine, Lilia and Sasso, Milene and Courtellemont, Laura and Bonnal, Christine and Rouges, Célia and Fekkar, Arnaud and Gits-Muselli, Maud and Senghor, Yaye and Guitard, Juliette and Cateau, Estelle and Huguenin, Antoine and Guegan, Hélène and Stoica, Maria-Alexandra and Tournus, Celine and Mahinc, Caroline and Letscher-Bru, Valérie and Limousin, Lucie and Guemas, Emilie and Roosen, Gabrielle and Desoubeaux, Guillaume and Thomas, Vincent and Pacreau, Marie-Liesse and Chachaty, Elisabeth and Lanternier, Fanny and Desnos-Ollivier, Marie},
title = {Assessing laboratory capacity for diagnosis of fungal infections in France: A multicentre survey within the SINFONI network},
journal = {Medical Mycology},
year = {2026},
volume = {64},
number = {5},
doi = {10.1093/mmy/myag050}
}
EUVIMED